Xeris Pharmaceuticals Competitors

Xeris Pharmaceuticals (NASDAQ:XERS) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, analyst recommendations, profitability and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Xeris Pharmaceuticals and Phibro Animal Health, as provided by MarketBeat.com.

Xeris Pharmaceuticals currently has a consensus target price of $13.00, suggesting a potential upside of 207.33%. Phibro Animal Health has a consensus target price of $21.50, suggesting a potential downside of 12.39%. Given Xeris Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Xeris Pharmaceuticals is more favorable than Phibro Animal Health.

Valuation and Earnings

This table compares Xeris Pharmaceuticals and Phibro Animal Health's revenue, earnings per share and valuation.

Phibro Animal Health has higher revenue and earnings than Xeris Pharmaceuticals. Xeris Pharmaceuticals is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Xeris Pharmaceuticals has a beta of 2.22, suggesting that its share price is 122% more volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500.

Insider & Institutional Ownership

69.3% of Xeris Pharmaceuticals shares are held by institutional investors. Comparatively, 50.3% of Phibro Animal Health shares are held by institutional investors. 6.1% of Xeris Pharmaceuticals shares are held by insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Xeris Pharmaceuticals and Phibro Animal Health's net margins, return on equity and return on assets.

Summary

Phibro Animal Health beats Xeris Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Xeris Pharmaceuticals (NASDAQ:XERS) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, analyst recommendations, profitability and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Xeris Pharmaceuticals and Enanta Pharmaceuticals, as provided by MarketBeat.com.

Xeris Pharmaceuticals currently has a consensus target price of $13.00, suggesting a potential upside of 207.33%. Enanta Pharmaceuticals has a consensus target price of $65.2857, suggesting a potential upside of 33.92%. Given Xeris Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Xeris Pharmaceuticals is more favorable than Enanta Pharmaceuticals.

Valuation and Earnings

This table compares Xeris Pharmaceuticals and Enanta Pharmaceuticals' revenue, earnings per share and valuation.

Enanta Pharmaceuticals has higher revenue and earnings than Xeris Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Xeris Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Xeris Pharmaceuticals and Enanta Pharmaceuticals' net margins, return on equity and return on assets.

Volatility and Risk

Xeris Pharmaceuticals has a beta of 2.22, suggesting that its share price is 122% more volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500.

Insider & Institutional Ownership

69.3% of Xeris Pharmaceuticals shares are held by institutional investors. Comparatively, 90.8% of Enanta Pharmaceuticals shares are held by institutional investors. 6.1% of Xeris Pharmaceuticals shares are held by insiders. Comparatively, 10.9% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Enanta Pharmaceuticals beats Xeris Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Arcturus Therapeutics (NASDAQ:ARCT) and Xeris Pharmaceuticals (NASDAQ:XERS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations and earnings.

Insider & Institutional Ownership

74.3% of Arcturus Therapeutics shares are held by institutional investors. Comparatively, 69.3% of Xeris Pharmaceuticals shares are held by institutional investors. 12.6% of Arcturus Therapeutics shares are held by company insiders. Comparatively, 6.1% of Xeris Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Arcturus Therapeutics and Xeris Pharmaceuticals, as reported by MarketBeat.com.

Arcturus Therapeutics presently has a consensus price target of $70.6667, suggesting a potential upside of 90.99%. Xeris Pharmaceuticals has a consensus price target of $13.00, suggesting a potential upside of 207.33%. Given Xeris Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Xeris Pharmaceuticals is more favorable than Arcturus Therapeutics.

Volatility & Risk

Arcturus Therapeutics has a beta of 3.01, indicating that its stock price is 201% more volatile than the S&P 500. Comparatively, Xeris Pharmaceuticals has a beta of 2.22, indicating that its stock price is 122% more volatile than the S&P 500.

Valuation & Earnings

This table compares Arcturus Therapeutics and Xeris Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Arcturus Therapeutics has higher revenue and earnings than Xeris Pharmaceuticals. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Xeris Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Arcturus Therapeutics and Xeris Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Arcturus Therapeutics beats Xeris Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Akero Therapeutics (NASDAQ:AKRO) and Xeris Pharmaceuticals (NASDAQ:XERS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Valuation and Earnings

This table compares Akero Therapeutics and Xeris Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Akero Therapeutics has higher earnings, but lower revenue than Xeris Pharmaceuticals. Akero Therapeutics is trading at a lower price-to-earnings ratio than Xeris Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Akero Therapeutics and Xeris Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Akero Therapeutics and Xeris Pharmaceuticals, as reported by MarketBeat.com.

Akero Therapeutics presently has a consensus price target of $57.2857, suggesting a potential upside of 106.36%. Xeris Pharmaceuticals has a consensus price target of $13.00, suggesting a potential upside of 207.33%. Given Xeris Pharmaceuticals' higher possible upside, analysts clearly believe Xeris Pharmaceuticals is more favorable than Akero Therapeutics.

Insider and Institutional Ownership

83.5% of Akero Therapeutics shares are owned by institutional investors. Comparatively, 69.3% of Xeris Pharmaceuticals shares are owned by institutional investors. 7.1% of Akero Therapeutics shares are owned by company insiders. Comparatively, 6.1% of Xeris Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Akero Therapeutics has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. Comparatively, Xeris Pharmaceuticals has a beta of 2.22, indicating that its share price is 122% more volatile than the S&P 500.

Summary

Akero Therapeutics beats Xeris Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

ESSA Pharma (NASDAQ:EPIX) and Xeris Pharmaceuticals (NASDAQ:XERS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, earnings and dividends.

Profitability

This table compares ESSA Pharma and Xeris Pharmaceuticals' net margins, return on equity and return on assets.

Insider & Institutional Ownership

63.4% of ESSA Pharma shares are owned by institutional investors. Comparatively, 69.3% of Xeris Pharmaceuticals shares are owned by institutional investors. 6.1% of Xeris Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares ESSA Pharma and Xeris Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

ESSA Pharma has higher earnings, but lower revenue than Xeris Pharmaceuticals. ESSA Pharma is trading at a lower price-to-earnings ratio than Xeris Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

ESSA Pharma has a beta of 1.96, indicating that its share price is 96% more volatile than the S&P 500. Comparatively, Xeris Pharmaceuticals has a beta of 2.22, indicating that its share price is 122% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for ESSA Pharma and Xeris Pharmaceuticals, as reported by MarketBeat.

ESSA Pharma presently has a consensus target price of $28.80, suggesting a potential upside of 1.52%. Xeris Pharmaceuticals has a consensus target price of $13.00, suggesting a potential upside of 207.33%. Given Xeris Pharmaceuticals' higher possible upside, analysts plainly believe Xeris Pharmaceuticals is more favorable than ESSA Pharma.

Summary

ESSA Pharma beats Xeris Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Xeris Pharmaceuticals (NASDAQ:XERS) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Profitability

This table compares Xeris Pharmaceuticals and Annexon's net margins, return on equity and return on assets.

Insider and Institutional Ownership

69.3% of Xeris Pharmaceuticals shares are held by institutional investors. Comparatively, 91.2% of Annexon shares are held by institutional investors. 6.1% of Xeris Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Xeris Pharmaceuticals and Annexon's gross revenue, earnings per share and valuation.

Annexon has lower revenue, but higher earnings than Xeris Pharmaceuticals.

Analyst Ratings

This is a breakdown of current ratings and target prices for Xeris Pharmaceuticals and Annexon, as provided by MarketBeat.

Xeris Pharmaceuticals currently has a consensus price target of $13.00, suggesting a potential upside of 207.33%. Annexon has a consensus price target of $34.3333, suggesting a potential upside of 37.72%. Given Xeris Pharmaceuticals' higher possible upside, equities research analysts clearly believe Xeris Pharmaceuticals is more favorable than Annexon.

Summary

Annexon beats Xeris Pharmaceuticals on 6 of the 10 factors compared between the two stocks.